RACHEL RESENDES: Open Payments
NPI 1760765499 · DARTMOUTH, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,424 in 77 payments from 24 companies in 2025. Trend: 2023 $1,147 · 2024 $1,581 · 2025 $1,424
Food & beverage: $1,424
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 14 | $277 |
| AstraZeneca Pharmaceuticals LP | 6 | $225 |
| Otsuka America Pharmaceutical, Inc. | 11 | $148 |
| ABBVIE INC. | 12 | $146 |
| MAYNE PHARMA COMMERCIAL LLC | 3 | $69 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $67 |
| Phathom Pharmaceuticals, Inc. | 5 | $66 |
| Verona Pharma, Inc. | 3 | $50 |
| SANOFI-AVENTIS U.S. LLC | 2 | $46 |
| Exact Sciences Corporation | 2 | $36 |
Products named: FARXIGA, REXULTI, VRAYLAR, Ozempic, Rybelsus, Wegovy, CAPLYTA, VOQUEZNA.
Industry payments across MA — which companies pay providers there.
